(Q33782365)

29 July 2017

1 reference

title

Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? (English)

1 reference

29 July 2017

1

Bombardier C

1 reference

29 July 2017

Maetzel A

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

Annals of the Rheumatic Diseases

29 July 2017

published in

1 reference

29 July 2017

volume

58 Suppl 1

1 reference

29 July 2017

page(s)

I82-5

1 reference

Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766572

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766572

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766572

The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766572

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766572

Discounting in the economic evaluation of health care interventions

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766572

Time preference in medical decision making and cost-effectiveness analysis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766572

Cost utility analysis: what should be measured?

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766572

4 July 2018

Valuing future benefits

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766572

Explanatory and pragmatic attitudes in therapeutical trials

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766572

Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766572

Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766572

Costs, effects and C/E-ratios alongside a clinical trial.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766572

The journal's policy on cost-effectiveness analyses.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1766572

In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care

30 October 2018

1 reference

12 December 2020

QALYs, HYEs, and the loss of innocence

1 reference

12 December 2020

Manufacturing consensus, marketing truth: guidelines for economic evaluation

1 reference

12 December 2020

Reporting guidelines for economic studies

1 reference

12 December 2020

The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs

1 reference

12 December 2020

Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij

1 reference

12 December 2020

An additional basic science for clinical medicine: II. The limitations of randomized trials

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.58.2008.I82

1 reference

29 July 2017

1 reference

29 July 2017

1 reference